Abstract: The present disclosure relates to methods of treating gastrointestinal stromal tumors to a subject in need thereof, comprising administering to the subject a therapeutically effective amount of ripretinib or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 20, 2022
Date of Patent:
April 30, 2024
Assignee:
Deciphera Pharmaceuticals, LLC
Inventors:
Rodrigo Ruiz Soto, Oliver Rosen, Jama Pitman
Abstract: Crystalline Forms of Compound (I): pharmaceutically acceptable salts thereof and solvates of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating disorders and conditions associated with oncogenic KIT and PDGFRA alterations using the same, and methods for making Compound (I) and crystalline forms thereof are also disclosed.
Abstract: Novel 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The 5-substituted aminopyrazino[2?,1?:2,3]imidazo[4,5-c][2,7]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: The invention provides compositions, compounds, formulations, and methods for treating HPV infections including pre-malignant infections and cancer. Compounds that covalently bind to the HPV E6 protein are disclosed.
Type:
Grant
Filed:
November 30, 2022
Date of Patent:
March 19, 2024
Assignees:
The Trustees of Indiana University, Kovina Therapeutics, Inc.
Inventors:
Elliot J. Androphy, Samy O. Meroueh, Zhijian Lu
Abstract: A 3-(2-(6-Methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine compound, its synthesis, and its use as an anticancer agent.
Type:
Grant
Filed:
September 13, 2023
Date of Patent:
March 19, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
Abstract: Described herein is a novel method for generation of recombinant poxviruses using an E3 and K3 double deletion mutant virus as the parental virus for generation of recombinant viruses. Following allowing for crossing over between the parental virus and an insertion cassette including an orthopox K3 peptide and the gene of interest, recombinant viruses are selected by infecting a host cell line permissive for the orthopox K3 peptide but not for the E3 and K3 double mutant parental virus. It is also demonstrated that a specific small molecule inhibitor of NEDD8 activating enzyme, MLN4924, can completely block poxvirus K3 family protein mediated PKR degradation and virus replication.
Type:
Grant
Filed:
March 22, 2019
Date of Patent:
March 19, 2024
Assignee:
Her Majesty the Queen in the Right of Canada as Represented by the Minister of Health
Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
Type:
Grant
Filed:
November 30, 2021
Date of Patent:
March 12, 2024
Assignee:
Incyte Corporation
Inventors:
Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
Abstract: Provided is a pharmaceutical composition for treating a tumor, which is used in combination therapy of lenvatinib and (6S,9aS)—N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide.
Abstract: The present application provides combination therapies comprising a JAK inhibitor and a ROCK inhibitor, and methods of using the same to treat disorders such as graft versus host disease (GVHD), restrictive allograft syndrome (RAS), chronic lung allograft dysfunction (CLAD), and systemic sclerosis (scleroderma).
Abstract: The invention provides compounds of Formula (I): as further described herein, as well as pharmaceutical compositions comprising such compounds, and methods to use the compounds and pharmaceutical compositions for treatment of certain viral disorders, including influenza.
Type:
Grant
Filed:
July 13, 2021
Date of Patent:
February 27, 2024
Assignee:
Novartis AG
Inventors:
Rama Jain, Dennis Christofer Koester, James R. Manning, Vanessa Marx, Daniel Poon, James Clifford Sutton, Benjamin R. Taft, Lifeng Wan, Aregahegn Yifru, Qian Zhao
Abstract: A 3-(2-(4-methoxypyridin-3-yl)-4,5-diphenyl-1H-imidazol-1-yl)-N,N-dimethylpropan-1-amine compound, its synthesis, and its use as an anticancer agent.
Type:
Grant
Filed:
September 12, 2023
Date of Patent:
February 20, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Hany Mohamed Abd El-Lateef Ahmed, Mai Mostafa Khalaf Ali, Antar Ahmed Abdelhamid Ahmed, Adel A. Marzouk
Abstract: Novel pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, a method of synthesizing said compounds, a pharmaceutical composition comprising said compounds and a suitable carrier, and a method of using the compounds. The pyrido[3?,4?:4,5]pyrrolo[3,2-c]naphthyridine compounds, identified as CK2 inhibitors, are useful as anticancer and/or antitumor agents, and as agents for treating other kinase-associated conditions including inflammation, pain, and certain immunological disorders, and other types of diseases such as diabetes, viral infection, neurodegenerative diseases.
Abstract: A compound 6-amino-8,9-di(4-methoxyphenyl)-2-oxo-3,9-dihydro-2H-[1,3]thiazolo[5?,4?:5,6]pyrano[2,3-b]pyridine-7-carbonitrile, its synthesis, and its use as an anticancer agent.
Type:
Grant
Filed:
August 29, 2023
Date of Patent:
February 13, 2024
Assignee:
KING FAISAL UNIVERSITY
Inventors:
Mai Mostafa Khalaf Ali, Hany Mohamed Abd El-Lateef Ahmed, Amer A. Amer, Antar Ahmed Abdelhamid Ahmed
Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
Type:
Grant
Filed:
March 1, 2021
Date of Patent:
February 13, 2024
Assignee:
AstaZeneca AB
Inventors:
Karl Magnus Nilsson, Annika Birgitta Margareta Åstrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepistö, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
Abstract: A compound of Formula II, or optionally a salt or a hydrate of the compound of Formula II is provided: wherein R1 is selected from the group consisting of a hydrogen, an alkyl group having from one to six carbon atoms, an aryl group, and a heteroaryl group; R2 is selected from the group consisting of an alkyl group having from one to six carbon atoms, a hydrogen, a NRaRb group wherein Ra is either a hydrogen or an alkyl group having from one to six carbon atoms and Rb is either a hydrogen or an alkyl group having from one to six carbon atoms, an aryl group, a heteroaryl group, and a halogen; R is an alkyl group having from one to six carbon atoms; and Ar is selected from the group consisting of an alkyl group having from one to six carbon atoms, a substituted aryl, and a substituted heteroaryl.
Abstract: Provided herein are, inter alia, compositions that bind to a PDZ1 domain of MDA-9/Syntenin (syndecan binding protein: SDCBP), thereby inhibiting MDA-9/Syntenin activity, and methods of use of same. The compositions and methods provided herein are useful for treating cancer and preventing cancer metastasis, particularly in cancers that have increased MDA-9/Syntenin expression.
Type:
Grant
Filed:
January 14, 2021
Date of Patent:
February 6, 2024
Assignees:
VIRGINIA COMMONWEALTH UNIVERSITY, SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE
Inventors:
Paul B. Fisher, Maurizio Pellecchia, Swadesh K. Das, Timothy P. Kegelman, Bainan Wu, Surya K. De, Jun Wei, Mitchell E. Menezes, Luni Emdad
Abstract: Cycloalkylamine derivatives may be used for preventing or treating diseases in humans, animals, and have demonstrated efficacy specifically in treating type 2 diabetes. In an embodiment, the cycloalkylamine derivatives can include a compound selected from the group consisting of cycloheptanamine salts, cyclohexanamine salts, cyclopentanamine salts 1-cycloheptyl-[4,4?-bipyridin]-1-ium, N1,N2-dicycloheptyloxalamide, 1-[3?,5?-bis(trifluoromethyl)phenyl]-3-cycloheptylurea, 1,1?-(4-methyl-1,3-phenylene)bis(3-cycloheptylurea), 1-(2?-aminopyrimidin-4?-yl)-3-cycloheptylurea, 4-amino-N-(cycloheptylcarbamoyl)benzenesulfonamide, 4-(3?-cycloheptylureido)-N-(5?-methylisoxazol-3?-yl)benzenesulfonamide, N-(cycloheptylcarbamoyl)-4-methylbenzenesulfonamide, 1-cycloheptylguanidine hydrochloride, (E)-amino[(amino(cycloheptylamino)methylene)amino]methaniminium chloride, or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
July 27, 2021
Date of Patent:
February 6, 2024
Assignee:
UNITED ARAB EMIRATES UNIVERSITY
Inventors:
Abdu Adem, Shaikha S. Al Neyadi, Ibrahim M. Abdou, Alaa A. Salem, Naheed Amir
Abstract: The present disclosure describes methods of treating pancreatic cancer and limiting over-expression of oncogenes, activating tumor suppressor genes or regulating signaling proteins in patients comprising administering compounds and pharmaceutical combinations as described herein.
Type:
Grant
Filed:
August 23, 2021
Date of Patent:
February 6, 2024
Assignee:
CHEMOCENTRYX, INC.
Inventors:
Petrus Bekker, Shichang Miao, Israel Charo, Tom Schall
Abstract: There are disclosed imidazolinopyrimidinone compounds that have activity to induce TRAIL gene expression in macrophages. There is further disclosed a method for treating various cancers comprising administering effective amounts of an imidazolinopyrimidinone having the structure of Formula I herein.
Type:
Grant
Filed:
July 12, 2021
Date of Patent:
February 6, 2024
Assignee:
The Scripps Research Institute
Inventors:
Kim D. Janda, Nicholas T. Jacob, Jonathan W. Lockner
Abstract: The invention includes methods of preventing or treating acute lung injury using a MAP3K2/MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.
Type:
Grant
Filed:
October 8, 2021
Date of Patent:
February 6, 2024
Assignee:
Yale University
Inventors:
Dianqing Wu, Qianying Yuan, Abdul Basit, Wenwen Tang